Rodney Dawson
Uppsala University(SE)Radboud University Nijmegen(NL)University of Cape Town(ZA)University of California, San Francisco(US)University Medical Center(US)Radboud University Medical Center(NL)Helmholtz Zentrum München(DE)Lung Institute(US)South African Tuberculosis Vaccine Initiative(ZA)Institute of Medical Microbiology and Hygiene(DE)Ludwig-Maximilians-Universität München(DE)
Publications by Year
Research Areas
Tuberculosis Research and Epidemiology, Mycobacterium research and diagnosis, Pneumocystis jirovecii pneumonia detection and treatment, Pneumonia and Respiratory Infections, Diagnosis and treatment of tuberculosis
Most-Cited Works
- → 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial(2012)429 cited
- → High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial(2016)382 cited
- → A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis(2015)315 cited
- → Evaluation of the Xpert MTB/RIF Assay for the Diagnosis of Pulmonary Tuberculosis in a High HIV Prevalence Setting(2011)309 cited
- → Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis(2015)249 cited
- → Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?